

**Question for written answer E-001822/2022  
to the Commission**  
Rule 138  
**Marc Botenga** (The Left)

Subject: Withdrawal by CureVac of vaccine candidate

The Commission has concluded an Advance Purchase Agreement, partially published on its website, for vaccines with CureVac. However, CureVac has withdrawn its vaccine candidate.

Against this backdrop:

1. Did CureVac's withdrawal of its COVID-19 vaccine candidate require that company to reimburse, fully or partially, the advance payment that it received under the Advance Purchase Agreement? If so, how much did it reimburse?
2. If not, does the Commission plan to ask for a reimbursement?
3. In the light of that announcement, has the Commission sought or obtained any other measures, such as the transfer by CureVac of equipment bought and of subcontractors' production capacity reserves, which could, among other uses, be allocated to other vaccine projects?